Most cited papers from Advaxis (United States)

Advaxis (United States)

What are the most cited papers from Advaxis (United States)?

The most cited paper from Advaxis (United States) is "The first clinical use of a live-attenuated Listeria monocytogenes vaccine: A Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix" (Paulo Maciag, Sinisa S. Radulovic, John Rothman, 2009), with 327 citations. Next come "Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer" (289) and "A Randomized Phase 2 Study of ADXS11-001 Listeria monocy'togenes-Listeriolysin O Immunotherapy With or Without Cisplatin in Treatment of Advanced Cervical Cancer" (184).

Published TypeFieldAccessAuthorsCitations

Showing 44 of 44 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	The first clinical use of a live-attenuated Listeria monocytogenes vaccine: A Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix Paulo Maciag, Sinisa S. Radulovic, John Rothman · Vaccine	4 May 2009	327
2	Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer Davide Melisi, Rocio García‐Carbonero, Teresa Mercade Macarulla et al. · British Journal of Cancer Open access	10 Oct 2018	289
3	A Randomized Phase 2 Study of ADXS11-001 Listeria monocy'togenes-Listeriolysin O Immunotherapy With or Without Cisplatin in Treatment of Advanced Cervical Cancer Partha Sarathi Basu, Ajay Omprakash Mehta, Minish Mahendra Jain et al. · International Journal of Gynecological Cancer Open access	14 Mar 2018	184
4	Targeting CCR8 Induces Protective Antitumor Immunity and Enhances Vaccine-Induced Responses in Colon Cancer Daniel O. Villarreal, Andrew L'Huillier, Susan Armington et al. · Cancer Research	19 Jul 2018	143
5	Development of a Listeria monocytogenes based vaccine against prostate cancer Vafa Shahabi, Mariela Reyes-Reyes, Anu Wallecha et al. · Cancer Immunology Immunotherapy Open access	13 Feb 2008	95
6	Development of a live and highly attenuated Listeria monocytogenes-based vaccine for the treatment of Her2/neu-overexpressing cancers in human Vafa Shahabi, Matthew M. Seavey, Paulo Maciag et al. · Cancer Gene Therapy	20 Aug 2010	82
7	Mage-b vaccine delivered by recombinant Listeria monocytogenes is highly effective against breast cancer metastases S H Kim, Francisco Castro, Daisy V. Gonzalez et al. · British Journal of Cancer Open access	19 Aug 2008	80
8	Construction and Characterization of an Attenuated Listeria monocytogenes Strain for Clinical Use in Cancer Immunotherapy Anu Wallecha, Paulo Maciag, Sandra Rivera et al. · Clinical and Vaccine Immunology Open access	20 Nov 2008	70
9	Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)-LLO immunotherapy Mikayel Mkrtichyan, Namju Chong, Rasha Abu Eid et al. · Journal for ImmunoTherapy of Cancer Open access	2013	68
10	HPV Variants and HLA Polymorphisms: The Role of Variability on The Risk of Cervical Cancer Patrícia Savio de Araujo‐Souza, Laura C. Sichero, Paulo Maciag · Future Oncology	17 Apr 2009	67
11	Live, attenuated strains of Listeria and Salmonella as vaccine vectors in cancer treatment Vafa Shahabi, Paulo Maciag, Sandra Rivera et al. · Bioengineered Bugs Open access	Jul 2010	65
12	A Novel Human Her-2/neu Chimeric Molecule Expressed by Listeria monocytogenes Can Elicit Potent HLA-A2 Restricted CD8-positive T cell Responses and Impact the Growth and Spread of Her-2/neu-positive Breast Tumors Matthew M. Seavey, Zhen-Kun Pan, Paulo Maciag et al. · Clinical Cancer Research	Feb 2009	57
13	Lm-LLO-Based Immunotherapies and HPV-Associated Disease Anu Wallecha, Chris A. French, Robert G. Petit et al. · Journal of Oncology Open access	2012	51
14	Episomal Expression of Truncated Listeriolysin O in LmddA-LLO–E7 Vaccine Enhances Antitumor Efficacy by Preferentially Inducing Expansions of CD4+FoxP3− and CD8+ T Cells Zhisong Chen, Laurent L. Ozbun, Namju Chong et al. · Cancer Immunology Research Open access	28 May 2014	49
15	A Core Stabilization Training Program for Tennis Athletes R. Barry Dale, Kim M. Samson, Michelle A. Sandrey et al. · Athletic Therapy Today	May 2007	48
16	ADXS31142 Immunotherapy ± Pembrolizumab Treatment for Metastatic Castration-Resistant Prostate Cancer: Open-Label Phase I/II KEYNOTE-046 Study Mark N. Stein, Lawrence H. Fong, Ronald F. Tutrone Jr. et al. · The Oncologist Open access	24 Feb 2022	47
17	A phase I study of MK-5108, an oral aurora a kinase inhibitor, administered both as monotherapy and in combination with docetaxel, in patients with advanced or refractory solid tumors Manik A. Amin, Susan E. Minton, Patricia Mucci LoRusso et al. · Investigational New Drugs Open access	30 Nov 2015	47
18	Listeria monocytogenes (Lm)-LLO Immunotherapies Reduce the Immunosuppressive Activity of Myeloid-derived Suppressor Cells and Regulatory T Cells in the Tumor Microenvironment Anu Wallecha, Reshma Singh, Inga V. Malinina · Journal of Immunotherapy	21 Oct 2013	45
19	Listeria monocytogenes-Derived Listeriolysin O Has Pathogen-Associated Molecular Pattern-Like Properties Independent of Its Hemolytic Ability Anu Wallecha, Laurence M. Wood, Zhen-Kun Pan et al. · Clinical and Vaccine Immunology Open access	8 Nov 2012	45
20	Live-attenuatedListeria-based immunotherapy John Rothman, Yvonne Y.W. Paterson · Expert Review of Vaccines	May 2013	41
21	Combined immunotherapy with Listeria monocytogenes-based PSA vaccine and radiation therapy leads to a therapeutic response in a murine model of prostate cancer Raquibul Hannan, Huagang Zhang, Anu Wallecha et al. · Cancer Immunology Immunotherapy Open access	26 May 2012	40
22	Interaction between polymorphisms of the Human Leukocyte Antigen and HPV-16 Variants on the risk of invasive cervical cancer Patrícia Savio de Araujo‐Souza, Paulo Maciag, Karina Braga Ribeiro et al. · BMC Cancer Open access	22 Aug 2008	34
23	Heterologous Prime/Boost Immunization With p53-based Vaccines Combined With Toll-like Receptor Stimulation Enhances Tumor Regression Hidenobu Ishizaki, Guang-Yun Song, Tumul Srivastava et al. · Journal of Immunotherapy Open access	15 Jun 2010	32
24	Cancer immunotherapy using recombinantListeria monocytogenes: Transition from bench to clinic Reshma Singh, Anu Wallecha · Human Vaccines Open access	May 2011	32
25	Analysis of human kallikrein 7 expression as a potential biomarker in cervical neoplasia Lara Termini, Paulo Maciag, Fernando Augusto Soares et al. · International Journal of Cancer	17 Nov 2009	28
26	Chapter 1 Multiple Effector Mechanisms Induced by Recombinant Listeria monocytogenes Anticancer Immunotherapeutics Anu Wallecha, Kyla Driscoll Carroll, Paulo Maciag et al. · Advances in applied microbiology Book chapter	2009	27
27	Listeria-derived ActA is an effective adjuvant for primary and metastatic tumor immunotherapy Laurence M. Wood, Zhen-Kun Pan, Vafa Shahabi et al. · Cancer Immunology Immunotherapy Open access	5 Mar 2010	26
28	A One Health overview, facilitating advances in comparative medicine and translational research Cheryl Stroud et al. · Clinical and Translational Medicine Open access	Aug 2016	23
29	Gene Ages, Nomenclatures, and Functional Diversification of the Methuselah/Methuselah‐Like GPCR Family in Drosophila and Tribolium Markus Friedrich, Jeffery W. Jones · Journal of Experimental Zoology Part B Molecular and Developmental Evolution	Dec 2016	21
30	ADXS11-001 immunotherapy targeting HPV-E7: final results from a Phase II study in Indian women with recurrent cervical cancer Robert G. Petit, Ajay Omprakash Mehta, Minish Mahendra Jain et al. · Journal for ImmunoTherapy of Cancer Open access	6 Nov 2014	21
31	Phase I/II study of ADXS11-001 or MEDI4736 immunotherapies alone and in combination, in patients with recurrent/metastatic cervical or human papillomavirus (HPV)-positive head and neck cancer Ezra E.W. Cohen, Kathleen N. Moore, Brian M. Slomovitz et al. · Journal for ImmunoTherapy of Cancer Open access	4 Nov 2015	20
32	ADXS11-001 immunotherapy targeting HPV-E7: updated survival and safety data from a phase 2 study in Indian women with recurrent/refractory cervical cancer Robert G. Petit, Partha Sarathi Basu · Journal for ImmunoTherapy of Cancer Open access	Nov 2013	19
33	Vaccine strain Listeria monocytogenes bacteremia occurring 31 months after immunization Elias Fares, Cindy B. McCloskey, Andres A. Gutierrez et al. · Infection	14 Nov 2018	18
34	31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two Casey R. Ager et al. · Journal for ImmunoTherapy of Cancer Open access1,802 authors	Nov 2016	17
35	31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one Andreas Lundqvist et al. · Journal for ImmunoTherapy of Cancer Open access1,762 authors	Nov 2016	11
36	Listeria monocytogenes Zach Z Liang, Ashley M. Sherrid, Anu Wallecha et al. · Human Vaccines & Immunotherapeutics Open access	10 Feb 2014	11
37	Phase I-II study of ADXS31-142 alone and in combination with pembrolizumab in patients with previously treated metastatic castration-resistant prostate cancer (mCRPC): the KEYNOTE-046 trial Naomi Balzer Haas, Mark N. Stein, Ronald F. Tutrone Jr. et al. · Journal for ImmunoTherapy of Cancer Open access	4 Nov 2015	11
38	The effect of P38 MAP kinase inhibition in a mouse model of influenza Ellena J. Growcott, Djibril Bamba, Jean-René Galarneau et al. · Journal of Medical Microbiology	24 Jan 2018	10
39	Phase II study of durvalumab alone or in combination with ADXS11-001 (AXAL) in recurrent/persistent or metastatic cervical cancer Brian M. Slomovitz, W.H. Bradley, Salil Ghamande et al. · Gynecologic Oncology	Oct 2020	4
40	High-dose treatment with ADXS11-001, a listeria monocytogenes (Lm)-listeriolysin O (LLO) immunotherapy, in women with cervical cancer Sharad A. Ghamande, David M. Mauro, Cheryl Price et al. · Journal for ImmunoTherapy of Cancer Open access	4 Nov 2015	3
41	Listeria monocytogenes personalized cancer vaccines drive therapeutic immune responses to cancer derived neoantigens Brandon Coder et al. · bioRxiv (Cold Spring Harbor Laboratory) PreprintOpen access	13 May 2020	1
42	Current awareness and use of bevacizumab in advanced cervical cancer: A survey among US community oncologists Heather J. Dalton, Aviva G. Asnis-Alibozek, Glynnis Mayes et al. · Gynecologic Oncology	Jun 2017	0
43	Lm-LLO immunotherapies targeting multiple antigens and their impact on different mechanisms in the tumor microenvironment Anu Wallecha, Poonam R. Molli · F1000Research Open access	27 Nov 2014	0
44	Biomarker identification in serum samples from patients with recurrent cervical cancer treated with ADXS11-001 immunotherapy Poonam R. Molli, Inga V. Malinina, Anu Wallecha · Journal for ImmunoTherapy of Cancer Open access	Nov 2013	0

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.